前列腺癌分期中68Ga-PSMA-11 PET/CT孤立肋骨摄取病灶的良恶性分析
这项回顾性单中心队列研究分析了2014年7月至2019年9月期间因前列腺癌初始分期接受68Ga-PSMA-11 PET/CT检查的男性,共62例仅见孤立肋骨PSMA摄取灶。61例(98.4%)符合良性标准,仅1例为假阴性恶性病灶(SUVmax 2.21,术后PSA 0.67 µg/L且随访进展)。结果表明绝大多数孤立肋骨摄取灶为低强度良性病变,通常无需干预确认。
要点
- 前列腺癌初始分期68Ga-PSMA-11 PET/CT中孤立肋骨PSMA摄取灶绝大多数(98.4%)为良性。
- 仅1例假阴性恶性病灶SUVmax为2.21,术后PSA 0.67 µg/L且随访进展。
- 43例(69.4%)良性肋骨病灶的SUVmax高于该恶性病灶的SUVmax。
核心结论
- 绝大多数前列腺癌初始分期中发现的孤立肋骨PSMA摄取灶为低强度良性病变,通常无需干预确认。
研究设计与样本
- 回顾性单中心三级转诊机构队列研究,纳入2014年7月至2019年9月因前列腺癌初始分期行68Ga-PSMA-11 PET/CT且仅见孤立肋骨PSMA摄取灶的男性62例。
- 54例行根治性前列腺切除术,8例行放疗。
主要发现
- 62例中61例(98.4%)符合良性肋骨病灶标准。
- 仅1例为假阴性恶性病灶,其肋骨病灶SUVmax为2.21,报告为良性,但术后PSA为0.67 µg/L,随访影像显示病灶进展并出现广泛转移。
- 良性肋骨病灶中4例被报告为可能转移(假阳性),其中3例行经皮肋骨活检,2例组织学良性、1例不确定;该不确定活检患者行根治性前列腺切除术,术后PSA<0.1 µg/L。
- 43例(69.4%)良性肋骨病灶的SUVmax高于上述恶性病灶的SUVmax。
关键数值与推荐
- 恶性判定标准:随访影像显示病灶增大。
- 良性判定标准:根治性前列腺切除术(RP)后PSA<0.1 µg/L;或放疗(RT)后PSA较最低值升高<2 µg/L(符合Phoenix标准);或肋骨活检组织学良性;或随访影像显示肋骨病灶无增大。
- 不符合上述标准者判定为不确定。
临床怎么用
- 对于前列腺癌初始分期68Ga-PSMA-11 PET/CT中发现的孤立肋骨PSMA摄取灶,可考虑为良性,通常无需干预确认。
- 需注意低SUVmax的孤立肋骨病灶仍存在恶性可能,应结合术后PSA和随访影像综合判断。
局限性
- 回顾性单中心研究,样本量较小(62例)。
- 仅1例恶性病灶,无法充分评估预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the proportion of solitary rib lesions on pre-treatment 68 Gallium-labelled prostate-specific membrane antigen (PSMA)/computed tomography (CT) scans in men with prostate cancer that are malignant and examine any predictive factors. PATIENTS AND METHODS: This retrospective single tertiary referral institution cohort study of men reviewed the results of 68 Ga-PSMA-11 positron emission tomography (PET)/CT scans performed for primary staging prior to treatment of prostate cancer from July 2014 to September 2019. Men with PSMA uptake outside the prostate in only the rib lesion were included. A solitary rib lesion was considered to be malignant if it increased in size on follow-up imaging. A lesion was considered benign if the prostate-specific antigen (PSA) level remained <0.1 µg/L following a radical prostatectomy (RP), <2 µg/L above nadir following radiotherapy (RT) as per the Phoenix criteria, histology was benign on rib biopsy, or follow-up imaging showed no growth of the rib lesion. If a lesion did not meet these criteria it was considered indeterminate. RESULTS: A total of 62 men had PSMA uptake in a solitary rib lesion; 54 went on to have RPs and eight underwent RT. In all, 61 of the men (98.4%) met the criteria for a benign rib lesion. Only one man had a false-negative malignant lesion. This man had a rib lesion with a low maximum standardised uptake value (SUVmax ) of 2.21 reported as benign, but the postoperative PSA level was 0.67 µg/L and the rib lesion progressed on follow-up imaging, with development of widespread metastases. Of the benign rib lesions, there were four false positives reported as possible metastases. Three had percutaneous rib biopsies, two of which came back with benign histology and one was indeterminate. The indeterminate biopsy patient had a RP and his postoperative PSA level was <0.1 µg/L. A total of 43 (69.4%) men with benign rib lesions had a SUVmax greater than the SUVmax of the malignant lesion. CONCLUSION: To our knowledge, this is the first cohort study of men with PSMA-avid solitary rib lesions on pre-treatment 68 Ga-PSMA PET/CT staging scans for prostate cancer. Our results indicate that the vast majority of these lesions have low-intensity uptake and are benign. Intervention to confirm this is not usually required.
引用
- Chen MY, Franklin A, Yaxley J, et al. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68 Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant? BJU Int. 2020. PMID: 32592330. doi:10.1111/bju.15152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。